Literature DB >> 18207586

Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: casuality or causality?

Silvia Migliaccio1, Giuseppe Barbaro, Rachele Fornari, Gabriella Di Lorenzo, Mauro Celli, Carla Lubrano, Stefania Falcone, Elisa Fabbrini, Emanuela Greco, Anna Zambrano, Marina Brama, Giancarlo Prossomariti, Sara Marzano, Mario Marini, Francesco Conti, Patrizia D'Eufemia, Giovanni Spera.   

Abstract

Osteogenesis imperfecta (OI) is a rare inherited connective disorder causing increased bone fragility and low bone mass. OI includes severe bone fragility, impaired dentinogenesis, with less common alterations in the joints, blood vessels, heart valves, skin. Interestingly, description of left ventricular rupture, aortic dissection and heart valves incompetence has been previously described. Death may occur in OI patients for cardiac disease in asyntomatic subjects. Aim of our study has been to evaluate the presence of potential subclinical cardiac disorders and to characterize cardiac functional parameters by echocardiography in adults with OI in absence of cardiac symptoms. Forty patients (21 females and 19 males) affected by type I, III, IV OI and 40 control subjects (20 females and 20 males) were evaluated in the study. Patients and controls underwent clinical examination, screening for endocrine and metabolic disorders, 12-lead electrocardiogram and echocardiogram. In particular, all subjects were evaluated by two-dimensional echocardiography with continuous- and pulse-wave Doppler. Patients and controls belonged to NYHA class I and no significant electrocardiographic alteration was documented in both groups. Thirty-eight patients (95%) showed valvular regurgitation compared to one control subject (2.5%; P<0.001). As regards the diastolic function parameters, in OI patients E wave velocity was reduced by 23% (95% CI: 9% to 29%; P<0.001), E/A ratio was reduced by 17% (95% CI: 15% to 26%; P<0.001) while isovolumetric relaxation time (IRT) was increased by 47% (95% CI: 26% to 53%; P<0.001) and E wave deceleration time (DT) was increased by 18% (95% CI: 13% to 26%; P<0.001) compared to controls. In conclusion, our data indicate that adult patients affected by OI have an altered diastolic function in absence of other metabolic alterations. These diastolic echocardiographic parameters might worsen over time, especially if other cardiovascular risk factors (e.g., smoking, hypertension, metabolic and endocrine alterations) are not carefully checked, monitored and treated. In the context of a multidisciplinary evaluation of OI patients, our data suggest that a careful cardiological evaluation of these patients is indicated beside skeletal evaluation and therapeutical skeletal options.

Entities:  

Mesh:

Year:  2008        PMID: 18207586     DOI: 10.1016/j.ijcard.2007.10.051

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

Review 1.  New perspectives on osteogenesis imperfecta.

Authors:  Antonella Forlino; Wayne A Cabral; Aileen M Barnes; Joan C Marini
Journal:  Nat Rev Endocrinol       Date:  2011-06-14       Impact factor: 43.330

2.  Evaluation of cardiac functions of patients with benign joint hypermobility syndrome.

Authors:  Sevket Balli; Mehmet Zafer Aydın; Vedat Gerdan; Ibrahim Ece; Mehmet Burhan Oflaz; Ayse Esin Kibar; Eylem Sen Dalkiran
Journal:  Pediatr Cardiol       Date:  2013-09-08       Impact factor: 1.655

3.  Echocardiographic Evidence of Early Diastolic Dysfunction in Asymptomatic Children with Osteogenesis Imperfecta.

Authors:  Khalfan S Al-Senaidi; Irfan Ullah; Hashim Javad; Murtadha Al-Khabori; Saif Al-Yaarubi
Journal:  Sultan Qaboos Univ Med J       Date:  2015-11-23

4.  Premature Atherosclerosis and Drug Eluting Stent Restenosis in an Adult with Osteogenesis Imperfecta.

Authors:  Mutlu Gungor; Mustafa Aparci; Ali C Özer
Journal:  Int J Angiol       Date:  2016-02-12

5.  Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study.

Authors:  Carla Lubrano; Marta Tenuta; Daniela Costantini; Palma Specchia; Giuseppe Barbaro; Sabrina Basciani; Stefania Mariani; Alfredo Pontecorvi; Andrea Lenzi; Lucio Gnessi
Journal:  Endocrine       Date:  2015-01-23       Impact factor: 3.633

6.  Cardiopulmonary Status in Adults with Osteogenesis Imperfecta: Intrinsic Lung Disease May Contribute More Than Scoliosis.

Authors:  Sobiah I Khan; Elizabeth A Yonko; Erin M Carter; Debra Dyer; Robert A Sandhaus; Cathleen L Raggio
Journal:  Clin Orthop Relat Res       Date:  2020-12       Impact factor: 4.755

7.  Genotype-phenotype correlation study in 364 osteogenesis imperfecta Italian patients.

Authors:  Margherita Maioli; Maria Gnoli; Manila Boarini; Morena Tremosini; Anna Zambrano; Elena Pedrini; Marina Mordenti; Serena Corsini; Patrizia D'Eufemia; Paolo Versacci; Mauro Celli; Luca Sangiorgi
Journal:  Eur J Hum Genet       Date:  2019-03-18       Impact factor: 4.246

Review 8.  Collagen transport and related pathways in Osteogenesis Imperfecta.

Authors:  Lauria Claeys; Silvia Storoni; Marelise Eekhoff; Mariet Elting; Lisanne Wisse; Gerard Pals; Nathalie Bravenboer; Alessandra Maugeri; Dimitra Micha
Journal:  Hum Genet       Date:  2021-06-24       Impact factor: 4.132

9.  Cardiopulmonary dysfunction in the Osteogenesis imperfecta mouse model Aga2 and human patients are caused by bone-independent mechanisms.

Authors:  Frank Thiele; Christian M Cohrs; Armando Flor; Thomas S Lisse; Gerhard K H Przemeck; Marion Horsch; Anja Schrewe; Valerie Gailus-Durner; Boris Ivandic; Hugo A Katus; Wolfgang Wurst; Catherine Reisenberg; Hollis Chaney; Helmut Fuchs; Wolfgang Hans; Johannes Beckers; Joan C Marini; Martin Hrabé de Angelis
Journal:  Hum Mol Genet       Date:  2012-05-15       Impact factor: 6.150

10.  Cardiovascular involvement in children with osteogenesis imperfecta.

Authors:  Hamdollah Karamifar; Homa Ilkhanipoor; Gholamhossein Ajami; Zohreh Karamizadeh; Gholamhossein Amirhakimi; Ali-Mohammad Shakiba
Journal:  Iran J Pediatr       Date:  2013-10       Impact factor: 0.364

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.